Comarch Named a Strong Performer in Loyalty Platforms Evaluation by Independent Research Firm
KRAKÓW, Poland, Dec. 9, 2025 /PRNewswire/ -- Comarch, a global provider of IT solutions and services, today announced its recognition as a Strong Performer in The Forrester Wave™: Loyalty Platforms, Q4 2025. The report, authored by John Pedini,...
Why Transparent, Comparable, and Reliable Security Testing Matters: AV-Comparatives Highlights 2025 Enterprise EPR and EDR Results
INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing has never been more critical. AV-Comparatives,...
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product...
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision...
DuPont Innovation Awards Recognize the Best PPE and Fabrics Against Emerging Risks
Winners demonstrate how Nomex® and Kevlar® fabrics and fibers can advance sustainability, multi-hazard protection, and firefighter safety. DÜSSELDORF, Germany, Nov. 18, 2025 /PRNewswire/ -- DuPont (NYSE: DD) today announced the winners of its 2025...
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its...
OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study
BELLEVUE, Wash., Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in collaboration with Korea University Guro Hospital. The...
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product...
DXC Named a Leader by IDC MarketScape in Worldwide AI Services for National Civilian Government
ASHBURN, Va., Nov. 3, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has been named a Leader in the "IDC MarketScape: Worldwide AI Services for National Civilian Government 2025 Vendor...
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been...